ERBB2 and ovarian carcinoma: Preliminary results are promising across all tumor types and correlate with HER2 expression with an ORR of 37.1% for all participants and 45% in the ovarian cohort (abstract LBA3000, abstract LBA34).14,15 It is unknown if clear cell carcinoma was represented in this trial as the ovarian cancer subtypes were not reported.